Cubist Systematic Strategies LLC Buys Shares of 26,287 ESSA Pharma Inc. (NASDAQ:EPIX)

Cubist Systematic Strategies LLC bought a new stake in ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 26,287 shares of the company’s stock, valued at approximately $47,000. Cubist Systematic Strategies LLC owned 0.06% of ESSA Pharma as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Magnus Financial Group LLC bought a new position in shares of ESSA Pharma in the fourth quarter worth about $99,000. BML Capital Management LLC bought a new position in shares of ESSA Pharma in the fourth quarter worth about $7,557,000. Lepercq Multi Asset Fund bought a new position in shares of ESSA Pharma in the fourth quarter worth about $54,000. Aldebaran Capital LLC bought a new position in shares of ESSA Pharma in the fourth quarter worth about $712,000. Finally, XTX Topco Ltd bought a new position in shares of ESSA Pharma in the fourth quarter worth about $67,000. Institutional investors own 75.12% of the company’s stock.

ESSA Pharma Stock Down 0.6%

NASDAQ EPIX opened at $1.70 on Tuesday. The stock’s 50-day moving average price is $1.65 and its 200-day moving average price is $1.70. ESSA Pharma Inc. has a 52 week low of $1.40 and a 52 week high of $7.88. The company has a market capitalization of $75.46 million, a P/E ratio of -2.46 and a beta of 1.69.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.05. Research analysts anticipate that ESSA Pharma Inc. will post -0.42 EPS for the current year.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.